Skip to main content.

David A. Duchene, M.D., FACS

David Duchene portrait
Professor, Urologic Surgery

Professional Background

Dr. David A. Duchene is an Associate Professor of Urology at the University of Kansas Health System and the Director of Minimally-Invasive Urological Surgery. He previously completed urology residency training at the University of Texas Southwestern Medical Center and then finished an Endourological Society fellowship at the University of Iowa Hospitals and Clinics.

Dr. Duchene is a graduate of the American Urological Association Leadership Program Class of 2014-2015. He is the past Kansas representative to the Board of Directors of the South Central Section of the AUA. He is currently the South Central Section representative on the Health Policy Committee of the AUA. He also serves on the New Technologies and Imaging Committee of the AUA. Dr. Duchene participates on the AACU UROPAC Board on behalf of the South Central Section.

Dr. Duchene is a past-president of the Kansas Urological Society. He enjoys being a section editor for “New Technologies in Endourology” Section of the Journal of Endourology. Dr. Duchene has written several peer-reviewed journal articles and text book chapters in the field of urology and serves as a reviewer for multiple publications, including the Journal of Urology, Urology, and the Journal of Endourology.

Education and Training
  • BS, Biology, Creighton University
  • MD, Medicine, University of Texas-Southwestern Medical School
  • Internship, General Surgery, Parkland Hospital/University of Texas Southwestern Medical Center, Dallas, Texas
  • Residency, Urology, Parkland Hospital/University of Texas Southwestern Medical Center, Da, Texas
  • Clinical Fellowship, Laparoscopy, robotics, and kidney stone disease, University of Iowa Hospitals and Clinics, Iowa City, Iowa

Research

Overview

Dr. Duchene participates in clinical research trials involving kidney stone treatment, kidney stone prevention, development of new minimally invasive surgical techniques, kidney cancer treatment, and prostate cancer treatment.